Yahoo
NYSE - Nasdaq Real Time Price USD

Boston Scientific Corporation (BSX)

44.83 +1.77 (+4.11%)
As of 2:22:47 PM EDT. Market Open.
Trade BSX on Coinbase
Chart Range Bar
Loading chart for BSX

Why is BSX moving today? Boston Scientific (BSX) rose 4.2% as strong sales growth in Neuromodulation and Interventional Oncology offset recent guidance cuts, outperforming the broader market's decline of 0.49%.

Boston Scientific (BSX) rose 4.2% as strong sales growth in Neuromodulation and Interventional Oncology offset recent guidance cuts, outperforming the broader market's decline of 0.49%.

Updated 6m ago · Powered by Yahoo Scout
  • Previous Close 43.06
  • Open 43.73
  • Bid 44.90 x 20000
  • Ask 44.91 x 100000
  • Day's Range 43.45 - 45.80
  • 52 Week Range 42.25 - 109.50
  • Volume 16,076,174
  • Avg. Volume 20,519,221
  • Market Cap (intraday) 66.633B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) 18.76
  • EPS (TTM) 2.39
  • Earnings Date Jul 29, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 75.00

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

www.bostonscientific.com

59,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 7/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BSX
52.98%
S&P 500 (^GSPC)
8.80%

1-Year Return

BSX
56.74%
S&P 500 (^GSPC)
19.60%

3-Year Return

BSX
17.12%
S&P 500 (^GSPC)
67.36%

5-Year Return

BSX
2.07%
S&P 500 (^GSPC)
71.13%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 5.2B
Earnings 1.19B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
1B
2B
3B
4B
5B

Analyst Insights

View More

Analyst Price Targets

55.00
75.00 Average
44.83 Current
106.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/25/2026
Analyst Stifel
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 75 -> 65

Statistics

View More

Valuation Measures

Annual
As of 7/1/2026
  • Market Cap

    64.00B

  • Enterprise Value

    73.58B

  • Trailing P/E

    18.02

  • Forward P/E

    12.84

  • PEG Ratio (5yr expected)

    0.52

  • Price/Sales (ttm)

    3.12

  • Price/Book (mrq)

    2.47

  • Enterprise Value/Revenue

    3.57

  • Enterprise Value/EBITDA

    13.39

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.29%

  • Return on Assets (ttm)

    6.07%

  • Return on Equity (ttm)

    14.66%

  • Revenue (ttm)

    20.61B

  • Net Income Avi to Common (ttm)

    3.56B

  • Diluted EPS (ttm)

    2.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.45B

  • Total Debt/Equity (mrq)

    42.25%

  • Levered Free Cash Flow (ttm)

    2.81B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

44.83 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Vickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional stock ownership trends. Form 13-Fs, which institutions must file to report their holdings, are due 45 days after the end of calendar quarters, and have now come in from 1Q26. We like to review the 13Fs of major activist investors -- including Carl Icahn, Trian Fund Management, Jana Partners, Starboard Value and ValueAct Holdings, among others -- in order to determine their core holdings and new purchases. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Activists have made progress in the past year, with high-profile investments into blue-chip companies such as Fedex and Union Pacific. Here are some recent new purchases and key holdings of activist investors, as well as other high-profile money managers.

    Vickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional stock ownership trends. Form 13-Fs, which institutions must file to report their holdings, are due 45 days after the end of calendar quarters, and have now come in from 1Q26. We like to review the 13Fs of major activist investors -- including Carl Icahn, Trian Fund Management, Jana Partners, Starboard Value and ValueAct Holdings, among others -- in order to determine their core holdings and new purchases. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Activists have made progress in the past year, with high-profile investments into blue-chip companies such as Fedex and Union Pacific. Here are some recent new purchases and key holdings of activist investors, as well as other high-profile money managers.

  • Based in Marlborough, Massachusetts, Boston Scientific is a developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, oncology, endoscopy, urology, gynecology, and neuromodulation. The company is a component of the S&P 500.

    Based in Marlborough, Massachusetts, Boston Scientific is a developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, oncology, endoscopy, urology, gynecology, and neuromodulation. The company is a component of the S&P 500.

    Rating
    Price Target
  • This is one of the busiest weeks of the year on Wall Street. There's a Fed rate meeting, which is also the last meeting with current-but-departing Chairman Jerome Powell. As well, five of the Mag7 are due to report earnings and there's a lot of economic data coming out (including updated on GDP and inflation). Last week, the Dow Jones Industrial Average and the S&P 500 were essentially flat, while the Nasdaq gained 1.5%. Year to date, all three indices are in positive territory. The Dow is up 2%, the S&P 500 is higher by 5%, and the Nasdaq is up 7%. On the earnings calendar, about 850 public companies are reporting this week. Highlights include Verizon on Monday; Visa, Coca-Cola, Novartis, Seagate Technology, Starbucks, and UPS on Tuesday; Alphabet, Microsoft, Amazon, and Meta Platforms on Wednesday; Apple, Eli Lilly, Merck, and Caterpillar on Thursday; and Exxon Mobil and Chevron on Friday. Turning to the economic calendar, the Case-Shiller Home Price Index will be reported on Tuesday; the Federal Reserve rate decision comes on Wednesday (followed by a final press conference hosted by Chairman Powell); and the Personal Consumption Expenditures Index inflation indicator and an update on GDP hit the tape on Thursday. The impact of the war is showing up in economic forecasts. Gas prices have been elevated, but fell eight cents last week and are now at an average of $4.04 per gallon for regular gas. The Atlanta Fed GDPNow forecast is now calling for 1.2% growth in 1Q, down from 3.0% about a month ago. The Cleveland Fed Inflation Nowcast forecast is at 3.6% for CPI in April, up from the 3.3% print in March. Mortgage rates moved lower last week, down seven basis points, with the average 30-year fixed-rate mortgage at 6.23%, according to FreddieMac. For the Federal Open Market Committee (FOMC) meeting this week, odds are at zero for a rate move. President Trump's nominee to be the next Fed chairman, Kevin Warsh, testified before Congress last week as he continues to move through the formal approval process. Of note, the controversial DOJ investigation into Chairman Powell was dropped. His term as Chairman expires on May 15, though he will remain on the committee. Taking a deeper dive into year-to date performance, a leading industrialized global stock market index, the ETF EFA, is up 5% year to date, while the leading emerging market ETF (EEM) is up 16%. U.S. growth stocks are flat year to date when looking at ETF IWF, and value stocks (IWD) are up 7%. Crude oil has pulled back from its high of $110 on April 7. On Friday, it was at $94 per barrel, still up 62% for the year. In other asset classes for the year to date, AGG bonds are flat, gold is up 8%, and Bitcoin is down 11%. The U.S. dollar is flat, tracking DXY. The VIX Volatility Index was about 19 on Friday, below its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026, as of March 31, is Energy (+27%), Materials (+14%), Industrials (+11%), Real Estate (+10%), Utilities (+9%), Consumer Staples (+9%), Information Technology (+8%), Communication Services (+5%), Consumer Discretionary (+2%), Financials (-5%), and Healthcare (-6%). By comparison, the S&P 500 is up 5% year to date.

    This is one of the busiest weeks of the year on Wall Street. There's a Fed rate meeting, which is also the last meeting with current-but-departing Chairman Jerome Powell. As well, five of the Mag7 are due to report earnings and there's a lot of economic data coming out (including updated on GDP and inflation). Last week, the Dow Jones Industrial Average and the S&P 500 were essentially flat, while the Nasdaq gained 1.5%. Year to date, all three indices are in positive territory. The Dow is up 2%, the S&P 500 is higher by 5%, and the Nasdaq is up 7%. On the earnings calendar, about 850 public companies are reporting this week. Highlights include Verizon on Monday; Visa, Coca-Cola, Novartis, Seagate Technology, Starbucks, and UPS on Tuesday; Alphabet, Microsoft, Amazon, and Meta Platforms on Wednesday; Apple, Eli Lilly, Merck, and Caterpillar on Thursday; and Exxon Mobil and Chevron on Friday. Turning to the economic calendar, the Case-Shiller Home Price Index will be reported on Tuesday; the Federal Reserve rate decision comes on Wednesday (followed by a final press conference hosted by Chairman Powell); and the Personal Consumption Expenditures Index inflation indicator and an update on GDP hit the tape on Thursday. The impact of the war is showing up in economic forecasts. Gas prices have been elevated, but fell eight cents last week and are now at an average of $4.04 per gallon for regular gas. The Atlanta Fed GDPNow forecast is now calling for 1.2% growth in 1Q, down from 3.0% about a month ago. The Cleveland Fed Inflation Nowcast forecast is at 3.6% for CPI in April, up from the 3.3% print in March. Mortgage rates moved lower last week, down seven basis points, with the average 30-year fixed-rate mortgage at 6.23%, according to FreddieMac. For the Federal Open Market Committee (FOMC) meeting this week, odds are at zero for a rate move. President Trump's nominee to be the next Fed chairman, Kevin Warsh, testified before Congress last week as he continues to move through the formal approval process. Of note, the controversial DOJ investigation into Chairman Powell was dropped. His term as Chairman expires on May 15, though he will remain on the committee. Taking a deeper dive into year-to date performance, a leading industrialized global stock market index, the ETF EFA, is up 5% year to date, while the leading emerging market ETF (EEM) is up 16%. U.S. growth stocks are flat year to date when looking at ETF IWF, and value stocks (IWD) are up 7%. Crude oil has pulled back from its high of $110 on April 7. On Friday, it was at $94 per barrel, still up 62% for the year. In other asset classes for the year to date, AGG bonds are flat, gold is up 8%, and Bitcoin is down 11%. The U.S. dollar is flat, tracking DXY. The VIX Volatility Index was about 19 on Friday, below its historical average of 20. Turning to sector performance, the list from first to worst so far in 2026, as of March 31, is Energy (+27%), Materials (+14%), Industrials (+11%), Real Estate (+10%), Utilities (+9%), Consumer Staples (+9%), Information Technology (+8%), Communication Services (+5%), Consumer Discretionary (+2%), Financials (-5%), and Healthcare (-6%). By comparison, the S&P 500 is up 5% year to date.

  • Argus is hosting a five-part webinar series on AI. Our first webinar was on AI and IT, and our most-recent event was on AI and Healthcare. Still to come are webinars on AI and the Consumer Sectors (April 1); AI and Financial Services (May 6); and AI and Industrial/Energy (June 3). In our recent webinar, we noted that Healthcare companies are using AI to improve research, surgeries, drug development, best practices, and other health-related enhancements. During the webinar, we were asked which Healthcare companies have strong records of innovation and are embracing breakthroughs in AI - and the following is a list of those companies, as we see it. They are all rated BUY at Argus.

    Argus is hosting a five-part webinar series on AI. Our first webinar was on AI and IT, and our most-recent event was on AI and Healthcare. Still to come are webinars on AI and the Consumer Sectors (April 1); AI and Financial Services (May 6); and AI and Industrial/Energy (June 3). In our recent webinar, we noted that Healthcare companies are using AI to improve research, surgeries, drug development, best practices, and other health-related enhancements. During the webinar, we were asked which Healthcare companies have strong records of innovation and are embracing breakthroughs in AI - and the following is a list of those companies, as we see it. They are all rated BUY at Argus.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: